Invivyd, Inc. (IVVD)
Nasdaq · Healthcare · Biotechnology
$0.8392+2.08%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $247M
- 52-week range
- $0.528 – $3.07
- 52-week change
- −42.11%
- EPS (trailing)
- −$0.33
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $53.4M (+110.47%)
- Net income
- −$52.5M
- Operating margin
- −104.0%
- Diluted EPS
- −$0.30
- Free cash flow
- −$58.3M
From the company’s annual report on SEC EDGAR.
About Invivyd, Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Headquarters: New Haven, United States · 122 employees · invivyd.com